A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trials

References

• Bebu, I., and J. M. Lachin. 2016. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. Biostatistics 17(1):178–187. January. doi: 10.1093/biostatistics/kxv032.
   PubMed Web of Science ®Google Scholar
• Berry, S. M., K. R. Broglio, S. Groshen, and D. A. Berry. 2013. Bayesian hierarchical modeling of patient subpopulations: Efficient designs of phase II oncology clinical trials. Clinical Trials 10 (5):720–734. doi:10.1177/1740774513497539.
   PubMed Web of Science ®Google Scholar
• Chen, C., X. Li, S. Yuan, Z. Antonijevic, R. Kalamegham, and R. A. Beckman. 2016. Statistical design and considerations of a phase 3 basket trial for simultaneous investigation of multiple tumor types in one study. Statistics in Biopharmaceutical Research 8 (3):248–257. doi:10.1080/19466315.2016.1193044.
   Web of Science ®Google Scholar
• Chu, Y., and Y. Yuan. 2018. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials 15 (2):149–158. doi:10.1177/1740774518755122.
   PubMed Web of Science ®Google Scholar
• Dong, G., B. Huang, J. Verbeeck, Y. Cui, J. Song, M. Gamalo-Siebers, D. Wang, D. C. Hoaglin, Y. Seifu, T. Mütze, et al. 2023. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes. Pharmaceutical Statistics 22(1):20–33. January. doi: 10.1002/pst.2251.
   PubMed Web of Science ®Google Scholar
• Food Drug Administration Center for Drug Evaluation Research. Expansion cohorts: Use in first-in-human clinical trials to expedite development of oncology drugs and biologics guidance for industry, 2018, Accessed May 1, 2021. https://www.fda.gov/media/115172/download
   Google Scholar
• Freidlin, B., and E. L. Korn. 2013. Borrowing information across subgroups in phase II trials: Is it useful? Clinical Cancer Research 19 (6):1326–1334. doi:10.1158/1078-0432.CCR-12-1223.
   PubMed Web of Science ®Google Scholar
• Lemery, S., P. Keegan, and R. Pazdur. 2017. First FDA approval agnostic of cancer site — When a biomarker defines the indication. The New England Journal of Medicine 377 (15):1409–1412. doi:10.1056/NEJMp1709968.
   PubMed Web of Science ®Google Scholar
• Luo, X., H. Tian, S. Mohanty, and W. Y. Tsai. 2015. An alternative approach to confidence interval estimation for the win ratio statistic. Biometrics 71 (1):139–145. doi:10.1111/biom.12225.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., S. Wandel, S. Roychoudhury, and S. Bailey. 2016. Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceutical Statistics 15 (2):123–134. doi:10.1002/pst.1730.
   PubMed Web of Science ®Google Scholar
• Péron, J., M. Buyse, B. Ozenne, L. Roche, and P. Roy. 2018. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research 27 (4):1230–1239. doi:10.1177/0962280216658320.
   PubMed Web of Science ®Google Scholar
• Pocock, S. J., C. A. Ariti, T. J. Collier, and D. Wang. 2012. The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European Heart Journal 33 (2):176–182. doi:10.1093/eurheartj/ehr352.
   PubMed Web of Science ®Google Scholar
• Simon, R. 1989. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10 (1):1–10. doi:10.1016/0197-2456(89)90015-9.
   PubMedGoogle Scholar
• Simon, R., S. Geyer, J. Subramanian, and S. Roychowdhury. 2016. The Bayesian basket design for genomic variant-driven phase II trials. Seminars in Oncology 43 (1):13–18. doi:10.1053/j.seminoncol.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Thall, P. F., J. K. Wathen, B. N. Bekele, R. E. Champlin, L. H. Baker, and R. S. Benjamin. 2003. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine 22 (5):763–780. doi:10.1002/sim.1399.
   PubMed Web of Science ®Google Scholar
• Wang, D., and S. Pocock. 2016. A win ratio approach to comparing continuous non-normal outcomes in clinical trials. Pharmaceutical Statistics 15 (3):238–245. doi:10.1002/pst.1743.
   PubMed Web of Science ®Google Scholar
• Wu, C., F. Liu, H. Zhou, X. Wu, and C. Chen. 2021a. Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials. Clinical Trials 18 (6):673–680. doi:10.1177/17407745211052486.
   PubMed Web of Science ®Google Scholar
• Wu, X., C. Wu, F. Liu, H. Zhou, and C. Chen. 2021b. A generalized framework of optimal two-stage designs for exploratory basket trials. Statistics in Biopharmaceutical Research 13 (3):286–294. doi:10.1080/19466315.2021.1906741.
   Web of Science ®Google Scholar
• Zhou, H., F. Liu, C. Wu, E. H. Rubin, V. L. Giranda, and C. Chen. 2019. Optimal two-stage designs for exploratory basket trials. Contemporary Clinical Trials 85:105807. doi:10.1016/j.cct.2019.06.021.
   PubMed Web of Science ®Google Scholar